AU2020244071A1 - System comprising a pre-fillable syringe and a package for the pre-fillable syringe - Google Patents
System comprising a pre-fillable syringe and a package for the pre-fillable syringe Download PDFInfo
- Publication number
- AU2020244071A1 AU2020244071A1 AU2020244071A AU2020244071A AU2020244071A1 AU 2020244071 A1 AU2020244071 A1 AU 2020244071A1 AU 2020244071 A AU2020244071 A AU 2020244071A AU 2020244071 A AU2020244071 A AU 2020244071A AU 2020244071 A1 AU2020244071 A1 AU 2020244071A1
- Authority
- AU
- Australia
- Prior art keywords
- syringe
- package
- cap
- replacement cap
- fillable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 229960001736 buprenorphine Drugs 0.000 claims description 7
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000005484 gravity Effects 0.000 description 12
- 239000002585 base Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000002562 thickening agent Substances 0.000 description 9
- -1 polytetrafluoroethylene Polymers 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 7
- 229920000663 Hydroxyethyl cellulose Chemical class 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 6
- 238000001746 injection moulding Methods 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000004354 Hydroxyethyl cellulose Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000013536 elastomeric material Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000020971 citrus fruits Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229940071643 prefilled syringe Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000167854 Bourreria succulenta Species 0.000 description 3
- 244000089742 Citrus aurantifolia Species 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 229960004543 anhydrous citric acid Drugs 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 3
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000019693 cherries Nutrition 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Chemical class 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Chemical class 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002845 Poly(methacrylic acid) Chemical class 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- SSNZFFBDIMUILS-UHFFFAOYSA-N dodec-2-enal Chemical compound CCCCCCCCCC=CC=O SSNZFFBDIMUILS-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical class COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- ZKWASVBZSAGDBI-UHFFFAOYSA-N 2,6-dimethyloctan-1-ol Chemical compound CCC(C)CCCC(C)CO ZKWASVBZSAGDBI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Chemical class 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Chemical class 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- YNKMHABLMGIIFX-UHFFFAOYSA-N benzaldehyde;methane Chemical compound C.O=CC1=CC=CC=C1 YNKMHABLMGIIFX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical class C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Chemical class 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002800 poly crotonic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/20—Closure caps or plugs for connectors or open ends of tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M5/3134—Syringe barrels characterised by constructional features of the distal end, i.e. end closest to the tip of the needle cannula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3213—Caps placed axially onto the needle, e.g. equipped with finger protection guards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
- A61M2005/3104—Caps for syringes without needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3117—Means preventing contamination of the medicament compartment of a syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/08—Supports for equipment
- A61M2209/084—Supporting bases, stands for equipment
Abstract
System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.
Description
SYSTEM COMPRISING A PRE-FILLABLE SYRINGE AND A PACKAGE FOR
THE PRE-FILLABLE SYRINGE
TECHNICAL FIELD
The invention relates to a package suitable and intended for receiving a pre-fillable syringe comprising a syringe barrel and a syringe tip, wherein the syringe tip is provided with a tip cap. The invention also relates to a system and the use of the system comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap. Further, the invention relates to a replacement cap for a pre-fillable syringe.
BACKGROUND
Pre-fillable syringes can be used as a kit together with the medium to be administered or delivered to the user, where the pre-fillable syringes of the kit are filled with the medium.
In particular, nowadays, pre-filled syringes have emerged as one of the fastest- growing choices for unit dose medication. The handling of such syringes is easy because the medium to administer does not need to be transferred to the syringe before the usage. The usage of pre-filled syringes minimizes drug waste and increases product life span.
The administration of drugs to patients, other than by an injection, has become more popular, due to the development of new drugs. Possible ways of administration are, in particular, oral, intranasal, topic, dermal and further external applications. For such applications, pre-filled syringes may be the best way to store, transport and administer the drugs.
Also, for mediums or drugs which are injected in the body, pre-filled syringes are a convenient choice. In particular, modem vaccines react very sensibly to outer influence factors and are therefore securely stored in a pre-filled syringe.
Pre-fillable syringe bodies comprise a syringe barrel, a syringe tip and optionally a finger flange. In some cases, the syringe tip is already provided with a piercing means. A
piercing means may be a needle, a canula, or a similar element.
The syringe bodies are produced by a primary packaging producer under clean room conditions. After a sterilization, the syringe bodies are provided with a tip cap and placed in a so-called syringe nest. The tip cap usually is placed on the syringe tip and may also enclose a needle arranged in the syringe tip.
The pre-fillable syringe is then delivered to a pharmaceutical company which either provide a kit together with the medium to administer or, preferably, fills the syringes with the medium.
In the latter case, after the filling process, a plunger or piston is introduced in the syringe barrel, by which the barrel is closed on its proximal side. The filled syringe is then placed in a secondary packaging.
The tip cap can seal the tip and optionally the needle. Usually, the tip caps are at least partially made of an elastic material. Due to the limited space for a syringe in the syringe nest, the tip caps are usually designed as small as possible. Such small sized tip caps may be, however, inconvenient for the user to handle.
In some cases, the user needs to set the dosage before the actual administration of the medium, which may be done at a later point. For this purpose, the tip cap may need to be temporally removed. The reclosing of the syringe with the tip cap may result in an unwanted introduction of a portion of air in the syringe barrel. Such a portion of air may cause irritations to the patient. In cases where the medium in the syringe barrel is a higher- viscosity medium, the enclosed portion of air may be difficult to remove.
WO 2018/038078 A1 discloses a medical equipment package with a plurality of syringe packaging bodies including a prefilled syringe system and a packaging main body, and an outer box which accommodates a plurality of syringe packaging bodies. A needle unit of the prefilled syringe system is supported with respect to a needle unit case with a largest outer diameter portion provided at a tip end of a needle hub engaging with an inner surface of the needle unit case. In the outer box, a plurality of syringe packaging bodies is arranged such that an axial direction of a needle body is in an up-and-down direction of the
outer box. The prefilled syringe is sealed with a sealing cap, however no replacement cap is provided.
SUMMARY OF THE INVENTION
An object of the invention is therefore to provide a pre-fillable syringe, package for receiving a pre-fillable syringe, and a system comprising a pre-fillable syringe and a package that overcomes the above-mentioned disadvantages.
The invention is also directed to the system of the invention, wherein the syringe is pre-filled with a ready-to-use pharmaceutical formulation.
Furthermore, the invention is directed to a kit comprising the system of the invention together with a pharmaceutical formulation in the form of either a ready-to-use aqueous solution or a powder to be reconstituted in a suitable vehicle, and instructions to administer said pharmaceutical formulation.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows a pre-fillable syringe without a tip cap;
Fig. 2a shows a pre-fillable syringe with a tip cap;
Fig. 2b shows a replacement cap;
Fig. 3 shows a pre-fillable syringe with a replacement cap;
Fig. 4 shows a pre-fillable syringe with a replacement cap on a support surface;
Fig. 5a shows a pre-fillable syringe with a tip cap, as in Fig. 2a;
Fig. 5b shows a replacement cap as in Fig. 2b, with different foot portion;
Fig. 6 shows a package body according to one embodiment without a pre-fillable syringe;
Fig. 7 shows a package body according to one embodiment with a pre-fillable syringe and a replacement cap;
Fig. 8 shows a package body according to one embodiment with a pre-fillable syringe placed in a replacement cap;
Fig. 9 shows a bottom perspective view of a plunger according to one or more embodiments;
Fig. 10 shows a top perspective view of the plunger;
Fig. 11 shows a bottom plan view of the plunger;
Fig. 12 shows a top plan view of the plunger; and
Fig. 13 shows a side view of the plunger.
LIST OF REFERENCE NUMERALS
1 package;
2 first receiving element;
3 package body;
4 first cavity of the package body;
5 sidewall of the package body;
6 bottom wall of the package body;
7 second receiving element;
7a first of the second receiving elements;
7b second of the second receiving elements;
8 third receiving element;
8a, 8b walls of the third receiving element ;
12 sidewall of the first receiving element;
13 height of the sidewall;
15 closure element;
26 semicircular top section of the second receiving element;
27 base section of the second receiving element;
30 fixture element;
31 flange;
100 pre-fillable syringe;
101 syringe barrel;
101a distal end of the syringe barrel
101b proximal end of the syringe barrel
102 syringe tip;
a outer diameter of the syringe tip;
tip cap;
a outer diameter of the tip cap;
b distal end face of the tip cap;
rod;
finger flange;
length of the pre-fillable syringe;
width of the finger flange;
width of the syringe barrel;
finger support;
region where the syringe barrel merges into the syringe tip; central axis of the pre-fillable syringe;
radius of the syringe barrel;
system;
replacement cap;
inner cap;
outer collar;
foot portion;
opening of the inner cap;
ring;
struts;
center axis of the replacement cap;
edge distance;
opening of the replacement cap;
a opening area of the replacement cap;
height;
bearing area;
distal end face of the foot portion;
313 edge of the bearing area;
314 cut portion;
400 support surface;
500 plunger;
501 ridges of plunger;
502 bottom of plunger;
X longitudinal axis of the package body;
Y horizontal axis of the package body;
Z vertical axis of the package body;
X’ longitudinal axis of the pre-fillable syringe;
Y’ horizontal axis of the pre-fillable syringe;
Z’ vertical axis of the pre-fillable syringe;
X” longitudinal axis of the replacement cap;
Y’’ horizontal axis of the replacement cap;
Z’’ vertical axis of the replacement cap;
X’ 1 distal direction
X’2 proximal direction;
L2 height of the central axis of the syringe above the bottom wall; and
L4 height of the sidewall of the package body.
DETAILED DESCRIPTION OF THE INVENTION
The problem is addressed by a system, comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, and wherein the package is suitable and intended for receiving the replacement cap.
The system has the advantage that a package, presented to the user, comprises the pre-fillable syringe to use and a suitable replacement cap. The user may retrieve the pre-fillable syringe from the package, remove the tip cap and optionally set the dosage of
the pre-fillable syringe. The replacement cap is already available to the user and does not need to be obtained otherwise. Further, the replacement cap does not need to be retrieved from an additional package. For such a retrieval of the replacement cap from the additional package, the user needs to put the possibly already open syringe down. Putting down the pre-fillable syringe could contaminate the syringe tip and implies an unnecessary complicated handling.
On the contrary, the system according to this invention provides the user the pre- fillable syringe and the replacement cap in one package. The replacement cap is therefore always available with the pre-fillable syringe and does not need to be obtained at a time, when the tip cap is possibly already removed. The mounting of the replacement cap may therefore be performed in an uncomplicated manner.
The further use of a replacement cap also has the advantage that the handling of the syringe is easier for the user, since it may be difficult to grasp and remove the comparatively small tip cap.
In the following, the expressions“distal” and“proximal” are understood such that a distal end of a syringe is closer to the application site as the proximal end. The expressions “distal direction” and“proximal directed” are understood analogously.
In the following, the longitudinal axis (X), horizontal axis (Y), and vertical axis (Z) are used in relation to the package body. The longitudinal axis (X’), horizontal axis (Y’), and vertical axis (Z’) are used in relation to the pre-fillable syringe. The longitudinal axis (X”), horizontal axis (Y”), and vertical axis (Z”) are used in relation to the replacement cap.
According to a preferred embodiment, the package comprises a package body forming a first cavity defined by a sidewall and a bottom wall. Preferably, the pre-fillable syringe is arrangeable in said first cavity. Preferably, the package body extends along a longitudinal axis (X), a horizontal axis (Y) and a vertical axis (Z), which are perpendicular to each other.
According to a preferred embodiment, at least one second receiving element is
provided in the first cavity of the package body, in which the syringe barrel is receivable. Preferably two second receiving elements are provided in the first cavity of the package body. Preferably, the at least one second receiving element is arranged on the bottom wall. It is further advantageous that the at least one second receiving element comprises a semicircular top section, arranged on a base section. The semicircular top section extends preferably along the horizontal axis (Y) and the longitudinal axis (X) and is open in the vertical axis (Z). Further, the semicircular top section is suitable and intended for receiving the syringe barrel. The semicircular top section comprises two arms which encompass the syringe barrel at least in part.
According to a further preferred embodiment a distal end of the syringe barrel is supported by a first of the second receiving elements and a proximal end of the syringe barrel is supported by a second of the second receiving elements. It is advantageous that a first of the second receiving elements is located close to or at the region where the syringe barrel merges into the syringe tip. Further, it is preferred that the second of the second receiving elements is located close to the finger flange of the syringe arranged in the package body. Preferably the first and the second of the second receiving elements are separated along the longitudinal axis (X’) of the pre-fillable syringe. Thus, in a state where the pre-fillable syringe is arranged in the package body and the syringe barrel is received by the preferably two second receiving elements, a central axis of the pre-fillable syringe extends preferably parallel to the bottom wall of the package body. Advantageously, the central axis extends in a height L2 above the bottom wall. The height L2 is dimensioned such that an easy grasping of the pre-fillable syringe is possible.
According to a further preferred embodiment, at least one third receiving element is provided in the first cavity of the package body, in which a rod of the pre-fillable syringe is receivable. Preferably, the third receiving element comprises two walls extending along the vertical axis (Z), forming a cavity in which the rod is received. Preferably, said walls extend along the longitudinal axis (X). Advantageously, the at least one third receiving element has a bottom wall which is formed semi circularly and connects said walls with
each other.
It is further advantageous that a gap between the second of the second receiving elements and the third receiving element is provided. Preferably a finger flange of the pre-fillable syringe projects through said gap such that the finger flange is sandwiched between second of the second receiving elements and the third receiving element. Through this gap, the finger flange of the pre-fillable syringe may preferably project, when the syringe is placed inside the package body. Since the finger flange is preferably sandwiched between the second of the second receiving elements and the third receiving element the pre-fillable syringe is fasted in the package body due to an engagement of the finger flange with the second of the second receiving elements and the third receiving element. The length of said walls is essentially determined by the length of a section of the rod, which projects from the syringe barrel, without the length of the rod in said gap between the second of the second receiving elements and the third receiving element.
According to a preferred embodiment, the pre-fillable syringe further comprises a plunger or a piston connected to a rod projecting out of the syringe barrel. Advantageously, the pre-fillable syringe comprises also a finger flange. The finger flange may be formed on the syringe barrel. It is also conceivable that a separate finger flange element is connected to the syringe barrel, which provides a larger gripping surface. The syringe tip is preferably formed as a cone. Advantageously, the syringe tip has a Luer-Cone. Currently, ISO 80369 governs the Luer standards. The syringe tip may preferably also be equipped with a piercing means, which may be a needle, a canula, or a similar means.
However, since it is intended for sublingual administration to neonates, preferably the syringe can be used without piercing means on the tip to avoid accidental harm to their mouth.
The pre-fillable syringe is advantageously provided with a tip cap, which is arranged on the syringe tip. The tip cap may consist at least in part of an elastomeric material. Advantageously, the pre-fillable syringe may consist of glass or plastics.
According to a preferred embodiment, the replacement cap is arranged in the
package, such that the replacement cap or an opening of the replacement cap is oriented along a vertical axis (Z) of the package body. Preferably, an opening area of the replacement cap is oriented parallel to the bottom wall of the package body. Such an arrangement allows an easy mounting of the replacement cap on the pre-fillable syringe. The replacement cap does not need to be removed from the package for the mounting process. The pre-fillable syringe may be inserted in the replacement cap, while the replacement cap still remains in the package. Once the replacement cap is mounted on the pre-fillable syringe, the replacement cap is removed together with the pre-fillable syringe from the package. This allows a handling of the syringe with only one hand. Obtaining a separate replacement cap may require a two-hand operation, since the replacement cap needs to be extracted from the separate package and needs to be oriented relative to the pre-fillable syringe, such that a mounting is possible.
According to a preferred embodiment, the replacement cap comprises an inner cap for an engagement with the syringe tip. Advantageously, the replacement cap comprises an outer collar engaging with the syringe barrel for mounting the replacement cap on the syringe barrel. Further, it is favorable that the replacement cap comprises a foot portion.
The inner cap is preferably arranged on the foot portion of the replacement cap. Advantageously, the inner cap may consist at least partially of an elastomeric material, such that a sealing connection with the syringe tip is possible. The syringe tip may preferably be introduced in the inner cap through an opening of the inner cap.
The outer collar is advantageously formed as a ring which is arranged along a longitudinal axis (X”) above the opening of the inner cap. The ring is preferably supported by struts which are arranged at the foot portion and surround the inner cap radially. Preferably, the three struts are placed along the circumference of the ring with an equal distance to each other. The struts project from the ring radially inward and abut at the syringe barrel, when the replacement cap is placed on the pre-fillable syringe.
Preferably, the opening area of the replacement cap is defined by the ring and the opening of the inner cap, which is placed along the longitudinal axis (X”) underneath the
opening of the ring. The opening of the ring and the opening are advantageously parallel to each other and share the same central axis. Preferably, the opening area of the replacement cap is defined by the ring. The opening area of the replacement cap, which is preferably defined by the ring, and an opening area of the inner cap are preferably oriented parallel to the bottom wall of the package body.
According to a preferred embodiment, a first receiving element is provided in the first cavity of the package body. Preferably, the replacement cap is received in the first receiving element. Advantageously, the foot portion of the replacement cap is received in the first receiving element. The replacement cap is therefore placed upright in the package. Thus, the opening area of the replacement cap is defined by the ring and an opening area of the inner cap are preferably oriented parallel to the bottom wall of the package body.
According to a preferred embodiment, the foot portion is suitable to provide a stable upright positioning of the pre-fillable syringe with the replacement cap on a support surface. Preferably, the foot portion comprises a bearing area which contacts the support surface. Preferably, the bearing area comprises an edge, which surrounds a center axis of the replacement cap at an edge-distance.
For a user, an upright positioning represents a very handy, practical way to place the pre-fillable syringe after removing it from the package. Under an upright positioning, a positioning of the distal end of the pre-fillable syringe on a supporting surface, is understood. Such a positioning bears the advantage that the proximal end is equipped with the finger flange and the rod is easy to grasp. A pre-fillable syringe typically has an extension which is by far larger along the longitudinal axis (X’) than along the horizontal axis (Y’).
A stable positioning is possible as long as the center of gravity is within an area defined by a tilting edge of the bearing area. The bearing area may stretch over a part of a distal end face of the replacement cap, which constitutes the distal end of the foot portion. It is also conceivable that the bearing area stretches over the entire distal end face. Further, it is conceivable that the bearing area stretches along the edge of the distal end face.
A displacement of the center of gravity in a radial direction may not affect the stability of the standing, as long as the center of gravity is not further radially outwards placed than the tilting edge. Due to the provision of a finger flange at the proximal end of the pre-fillable syringe, the center of gravity is closer to the proximal end of the syringe. This means that a small displacement of the center of gravity can cause the upright standing syringe to topple.
Preferably, the edge-distance between the edge of the bearing area and the center axis is at least twice the radius of the syringe barrel, more preferably, the edge-distance is at least three times the radius of the syringe barrel. Preferably, the edge-distance is at least four times the radius of the syringe barrel. Preferably, the edge-distance is at least five times the radius of the syringe barrel. Due to such an embodiment, the tilting edge is further away from the center axis. Thus, a larger displacement of the center of gravity is possible, before the upright standing syringe topples. Hence, the standing stability is enhanced.
Preferably, the distal end face of the foot portion comprises an edge, surrounding a center axis of the replacement cap at a certain distance. This edge may preferably be parallel to the edge of the bearing area, which is considered as a tilting edge. The edge of the distal end face defines the shape of the foot section, which can be arbitrary. Advantageously, the foot portion has a disc-like shape. Preferably, the foot portion is essentially circular. Alternatively, the foot portion can be rectangular.
After the described equipping of the syringe with a replacement cap, which may be done only one-handed, due to the preferable placement and orientation of the replacement cap in the package, the syringe may be placed standing upright and is easily accessible for the user, when needed.
According to a preferred embodiment, the bearing area and/or the edge surrounding the bearing face is/are coated at least partially with a rubberized material. Such an embodiment bears the advantage that slipping of the foot portion on the supporting surface is inhibited or minimized.
According to a preferred embodiment, the foot portion is designed as a suction cup.
A suction cup is a device or object that uses the negative fluid pressure of air to adhere to nonporous surfaces, creating a partial vacuum. The working face of the foot portion is preferably made of elastic, flexible material and has a curved surface. When the center of the foot portion is pressed against a flat supporting surface, the volume of the space between the foot portion and the flat surface is reduced. Thus, the air or water between the foot portion and the surface is to be expelled past the edge of the cup. By this, a lack of pressure develops between the foot portion and the supporting surface. The pressure difference between the atmosphere on the outside of the foot portion and the low-pressure between the foot portion and the supporting surface keeps the foot portion adhered to the surface.
Preferably, the replacement cap is produced by injection molding, preferably by multi-component injection molding.
According to a further preferred embodiment, the sidewall of the package body extends essentially along a vertical axis (Z). By extending essentially, it is meant that the sidewall may have a comparatively small angle (a) to the vertical axis (Z). Such an angle could be in a range between 0° to 25°, preferably 0° to f 0°, preferably 0° to 5°.
Advantageously, the sidewall of the package body is provided with a flange on its upper end, wherein the flange extends outwards essentially along the longitudinal (X) or the horizontal (Y) axis. Preferably, the flange surrounds the package body.
According to a further preferred embodiment, the package comprises a closure element, which covers the package body at least in part. Preferably, the closure element covers the package body entirely.
According to a further preferred embodiment, the closure element is arranged on the flange, provided on the side walls. The closure element could be a foil or a dimensionally stable element. The closure element could preferably be connected to the flange by a clamping connection, a snap connection, a welded connection or an adhesion bond, or similar connections. Preferably, before the usage, such a connection is torn off, preferably before the usage in order to expose the pre-fillable syringe in the package body.
According to a further preferred embodiment, the closure element is slidably
arranged on the package body. Preferably, the closure element is slidable along a slide direction, which is preferably oriented along the longitudinal direction (X). Advantageously, the closure element is provided with a guidance element, which extends along the slide direction, in particular the longitudinal direction (X) on each edge, extending in the direction of the closure element. Preferably, each flange of the two sidewalls extending in the slide direction, in particular the longitudinal direction, is received in a guidance element.
According to a further preferred embodiment, the package may consist of plastic. Preferably, the package is produced in an injection molding process, preferably in a multi-component injection molding process.
The object is also addressed by a package suitable and intended for receiving a pre-fillable syringe comprising a syringe barrel and a syringe tip, wherein the syringe tip is provided with a tip cap, wherein the package is suitable and intended for receiving a replacement cap for the pre-fillable syringe.
The package may comprise the single features or combinations of the features described above for the system. Also, the system may comprise the single features or combinations of the features described for the package. Further, the same advantages may apply for the package as described above for the system.
According to a preferred embodiment, the package comprises a package body, forming a first cavity defined by a sidewall and a bottom wall. Preferably, the pre-fillable syringe is arranged in said first cavity. Advantageously, at least one second receiving element is provided in the first cavity of the package body, in which the syringe barrel is received.
According to a further preferred embodiment a distal end of the syringe barrel may be supported by a first of the second receiving elements and a proximal end of the syringe barrel may be supported by a second of the second receiving elements. It is advantageous that a first of the second receiving elements may be located close to or at the region where the syringe barrel merges into the syringe tip. Further, it is preferred that the second of the
second receiving elements may be located close to the finger flange of the syringe arranged in the package body. Preferably the first and the second of the second receiving elements are separated along the longitudinal axis (X’) of the pre-fillable syringe. Thus, in a state where the pre-fillable syringe is arranged in the package body and the syringe barrel is received by the preferably two second receiving elements, a central axis of the pre-fillable syringe extends preferably parallel to the bottom wall of the package body. Advantageously, the central axis extends in a height L2 above the bottom wall of the package body.
According to a preferred embodiment, a first receiving element is provided in the first cavity of the package body. Preferably, the replacement cap is received in the first receiving element, such that the replacement cap is oriented along a vertical axis (Z) of the package body and an opening area of the replacement cap is oriented parallel to the bottom wall of the package body. Preferably, the foot portion of the replacement cap is received in the first receiving element. Preferably a bearing area of the replacement cap contacts the bottom wall of the package body.
The object is also addressed by a replacement cap for a pre-fillable syringe, wherein the replacement cap comprises an inner cap for an engagement with the syringe tip, an outer collar engaging with the syringe barrel for mounting the replacement cap on the syringe barrel and a foot portion replacement cap comprising a foot portion, which is suitable to provide a stable upright positioning of the syringe with the replacement cap on a surface.
The replacement cap may comprise the single features or combinations of the features described above for the system. Also, the system may comprise the single features or combinations of the features described for the replacement cap. Further, the same advantages may apply for the replacement cap as described above for the system.
The inner cap is preferably arranged on the foot portion of the replacement cap. Advantageously, the inner cap may consist at least partially of an elastomeric material, such that a sealing connection with the syringe tip is possible. The syringe tip may preferably be introduced in the inner cap through an opening of the inner cap.
The outer collar is advantageously formed as a ring which is arranged along a vertical axis (Z’) above the opening of the inner cap. The ring is preferably supported by struts which are arranged at the foot portion and surround the inner cap radially. Preferably, the three struts are placed along the circumference of the ring with an equal distance to each other. The struts project from the ring radially inward and abut at the syringe barrel, when the replacement cap is placed on the pre-fillable syringe.
Preferably, the opening area of the replacement cap is defined by the ring and the opening of the inner cap, which is placed along the vertical axis (Z) underneath the opening of the ring. The opening of the ring and the opening are advantageously parallel to each other and share the same central axis. Preferably, the opening area of the replacement cap is defined by the ring. The opening area of the replacement cap, which is defined by the ring, and an opening area of the inner cap are preferably oriented parallel to the bottom wall of the package body.
According to a preferred embodiment, the foot portion is suitable to provide a stable upright positioning of the pre-fillable syringe with the replacement cap on a surface. For a user, an up-right positioning represents a very handy, practical way to place the syringe. An upright positioning can mean a positioning of the distal end on a supporting surface, such that the proximal end, equipped with the finger flange and the rod, is easy to grasp.
Preferably, the foot portion comprises an edge, surrounding a center axis of the replacement cap. This edge may be considered as the above-mentioned tilting edge. The edge defines the shape of the foot section, which can be arbitrary. Preferably, the foot portion has a disc-like shape. Advantageously, the foot portion has a disc-like shape. Preferably, the foot portion has an essentially circular base area. Preferably, the foot portion has a base area which is essentially rectangular. Preferably, the distance between the edge and the center axis is at least twice the radius of the syringe barrel, more preferably the distance between the edge and the center axis is at least three times the radius of the syringe barrel. Preferably, the distance between the edge and the center axis is at least four times the radius of the syringe barrel. Preferably, the distance between the edge and the center
axis is at least five times the radius of the syringe barrel. Due to such an embodiment, the tilting edge is further away from the center axis. Thus, a larger displacement of the center of gravity is possible before the up-right standing syringe topples. Hence, the standing stability is enhanced.
After the described equipping of the syringe with a replacement cap, which may be done only one-handed, due to the preferable placement and orientation of the replacement cap in the package, the syringe may be placed upright standing and is easily accessible for the user, when needed.
According to a preferred embodiment, the bearing area and/or the edge surrounding the bearing face is/are coated at least partially with a rubberized material. Such an embodiment bears the advantage that slipping of the foot portion on the supporting surface is inhibited.
According to a preferred embodiment, the foot portion is designed as a suction cup. A suction cup is a device or object that uses the negative fluid pressure of air to adhere to nonporous surfaces, creating a partial vacuum. The working face of the foot portion is preferably made of elastic, flexible material and has a curved surface. When the center of the foot portion is pressed against a flat supporting surface, the volume of the space between the foot portion and the flat surface is reduced. Thus, the air or water between the foot portion and the sur-face is to be expelled past the edge of the cup. By this, a lack of pressure develops between the foot portion and the supporting surface. The pressure difference between the atmosphere on the outside of the foot portion and the low-pressure between the foot portion and the supporting surface keeps the foot portion adhered to the surface.
Preferably, the replacement cap may consist of a plastics material. Preferably the replacement cap is produced by injection molding, preferably by multi-component injection molding.
The object is also addressed by a use of a system according to any of the above- mentioned embodiments, comprising the following steps,
a) retrieving the pre-fillable syringe from the package;
b) removing the tip cap from the syringe tip;
c) placing the syringe tip in the replacement cap, which is arranged in the package; and
d) retrieving the pre-fillable syringe with the replacement cap attached to it from the package.
The use of the system may comprise the single features or combinations of the features described above for the system or package. Also, the system or the package may comprise the single features or combinations of the features described above for the use. Further, the same advantages may apply for the use of the system as described above for the system or the package.
According to a preferred embodiment, the use comprises the step to set the dosage of the pre-fillable syringe.
According to a preferred embodiment, the usage may also comprise the step of removing the closure element.
According to a preferred embodiment, the syringe may be placed in an upright position on a support surface after the retrieval of the syringe equipped with the replacement cap of the package. Preferably, a foot portion of the replacement cap is suitable to provide a stable upright positioning of the pre-fillable syringe with the replacement cap on the support surface. Preferably, a bearing area of a foot portion of the replacement cap contacts the support surface.
In the following, the longitudinal axis (X), horizontal axis (Y), and vertical axis (Z) are used in relation to the package body (3). The longitudinal axis (X’), horizontal axis (Y’), and vertical axis (Z’) are used in relation to the pre-fillable syringe (100). The longitudinal axis (X”), the horizontal axis (Y”), and the vertical axis (Z”) are used in relation to the replacement cap (300).
In Figs. 1, 2a, 3, 4, and 5a, a pre-fillable syringe is displayed. A pre-fillable syringe (100) comprises a syringe barrel (101) and a syringe tip (102). The syringe barrel (101) is cylindrically shaped and open at its proximal end. At its distal end, the syringe barrel (101)
merges along the distal direction (X’ 1) into the syringe tip (102). The syringe tip (102) may have the form of a cone. Advantageously, the syringe tip (102) is a Luer-cone. Although not necessarily preferred, it is also conceivable that a piercing means, in particular a needle, a canula, or a similar means, is arranged in the syringe tip (102). In the syringe barrel (101), the medium to administer is stored. On its proximal end, the syringe barrel (101) is closed with a plunger or a piston 500, such as shown in figures 9-13), which is movable in the syringe barrel (101).
In a preferred embodiment, the plunger 500, as shown in Figs. 9-13, can have a flat surface on the bottom 502 thereof instead of a conic section as in a standard plunger. The bottom flat surface 502 of the plunger 500 allows a better dose adjustment. The lateral wall of the plunger has annular ridges 501 for a sealing sliding within the syringe barrel 101.
More preferably the plunger can be fully coated with silicone, Teflon, or the like, even more preferably with a film of polytetrafluoroethylene (PTFE).
With standard plunger stoppers and siliconized barrels the Break-Loose-Force (BLF) of the plunger stopper can increase while storage duration of the filled syringe. The Glide-Force (GF) may not see this increase while in storage. Therefore, the difference between the two (2) forces (AF) can increase over storage duration. This can lead to the following user-experience after storage: the user increases the push-force onto a plunger rod until the plunger stopper moves. With a relatively high difference between Break- Loose-Force & Glide-Force, the user may not able to stop the force quick enough to be able to set a small dose difference.
Furthermore, according to the present invention, the coating favors an easiest actuation of the device of the invention and lowest level of subvisible particulates.
The plunger or the piston (e.g., as in Figs. 9-13) can be attached to a rod (104), which projects in the proximal direction (X’2) from the syringe barrel (101). On the proximal end of the rod (104), a finger support (109) is arranged. Further, the syringe barrel (101) is provided with a finger flange (105). In the present case, the finger flange (105) is a clip-on-finger flange which may be clipped on a finger flange on the syringe barrel (101).
Such clip-on-finger flanges bear the advantage of a larger area to grasp for the user.
The pre-fillable syringe (100) is provided with a tip cap (103) which is arranged on the syringe tip (102). The tip cap (103) may consist at least in part of an elastomeric material.
In Figs. 2b and 5b, a replacement cap (300) is depicted. In Figs. 3, 4 and 8, a pre-fillable syringe (100) is depicted, which is equipped with a replacement cap (300). In Figs. 7, 8 and 10, a package (1) is shown, in which a replacement cap (300) is arranged.
The replacement cap (300) comprises an inner cap (301) for an engagement with the syringe tip (102). The inner cap (301) is arranged on a foot portion (303) of the replacement cap. Preferably, the inner cap (301) may consist at least partially of an elastomeric material, such that a sealing connection to the syringe tip (102) is possible. The syringe tip (102) may be introduced in the inner cap (301) through the opening (304) of the inner cap (301).
Further, the replacement cap (300) comprises an outer collar (302) engaging with the syringe barrel (101) for mounting the replacement cap (300) and a foot portion (303).
The outer collar (300) comprises a ring (305) which is arranged along the longitudinal axis (X”) above the opening (304) of the inner cap (301). The ring (305) is supported by struts (306). Preferably, three struts (306) are placed along the circumference of the ring (305) with an equal radial distance to each other. The struts (306) are arranged at the foot portion (303) and surround the inner cap (301) radially. Further, the struts (306) project from the ring (305) radially inward and abut at the syringe barrel (101), when the replacement cap (300) is placed on the pre-fillable syringe (100).
The replacement cap (300) comprises an opening (309) and an opening area (309a), which is defined by the ring (305). The opening (304) of the inner cap (301) is placed along the longitudinal axis (X’’) underneath the ring opening (309). Thus, the opening area (309a) is oriented parallel to an opening area of the opening (304) of the inner cap (301). The pre-fillable syringe (100) is introduced first through the opening (309) and then into the opening (304) of the inner cap (301). The opening (309) and the opening (304) share the
same center axis (307). In Figs. 7 and 8, a package (1) is shown, in which a replacement cap (300) is arranged. The opening area (309a) is then oriented parallel to the bottom wall (6) of the package body (3).
The foot portion (303) is suitable to provide a stable upright positioning of the pre-fillable syringe (100) on a support surface (400). This is depicted in Fig. 4. Under an upright positioning a positioning of the distal end of the pre-fillable syringe (100) on a support surface (400) is understood, such that the proximal end of the pre-fillable syringe (100), which is equipped with the finger flange (105) and the rod (104), is easy to grasp. The foot portion (303) comprises a bearing area (311), which contacts the supporting surface (400). The bearing area (311) may stretch over a part of a distal end face (312) of the replacement cap (300), which constitutes the distal end of the foot portion. It is also conceivable that the bearing area (311) stretches of the entire distal end face (312). Further, it is conceivable that the bearing area (311) stretches along the edge of the distal end face (312).
The pre-fillable syringe (100) has an extension which is by far larger along the longitudinal axis (X’) than along the horizontal axis (Y’). A stable positioning is possible as long as the center of gravity is within an area defined by an edge of the bearing area (311). A displacement of the center of gravity in a radial direction (along the horizontal axis (Y’) or the vertical axis (Z’)) may not affect the stability of the standing as long as the center of gravity is not further radially outwards placed than the tilting edge. Due to the provision of a finger flange (105) at the proximal end of the pre-fillable syringe (100), the center of gravity is closer to the proximal end of the pre-fillable syringe (100). This means that a small displacement of the center of gravity causes the upright standing syringe to topple.
The bearing area (311) comprises an edge (313) which surrounds a center axis (307) of the replacement cap (300) at an edge-distance (308). The edge-distance (308) is at least twice the radius (112) of the syringe barrel (101), more preferably the edge-distance (308) is at least three times the radius (112) of the syringe barrel (101). Preferably, the
edge-distance (308) is at least four times the radius (112) of the syringe barrel (101). Preferably, the edge-distance (308) is at least five times the radius (112) of the syringe barrel (101). Due to such an embodiment, the tilting edge is further away from the center axis. It is therefore a larger displacement necessary to tip the pre-fillable syringe (100) over.
The distal end face (312) of the foot portion (303) comprises an edge. The edge of the distal end face (312) and the edge (313) of the bearing area (311) are parallel to each other and adjacent.
In the Figs. 2b, 3, 4, 7, and 8, the replacement cap (300) has a disc-like shape which is essentially circular, except for a cut portion (314). Said edge distance (308) is therefore essentially the radius of the disc-like shaped foot portion (313). The cut portion (314) extends along a secant line, meaning a line that intersects the circular replacement cap on two points of the diameter, wherein the secant does not run through the center of the circular replacement cap. The cut portion (314) is adjacent to a sidewall (5) extending along the longitudinal axis (X).
The foot portion (303) according an embodiment of Fig. 5b is rectangular. The edge-distance (308) would therefore be the distance to the edge closest to the center axis (307).
The foot portion (303) is, due to its dimension, also a suitable grip portion for the user to grasp the replacement cap (300). The foot portion (303) may also be designed as a suction cup, which is a device or object that uses the negative fluid pressure of air to adhere to nonporous surfaces, creating a partial vacuum.
In the Figs. 6 to 8, a package (1) and/or a system (200) are depicted.
The system (200) comprises a pre-fillable syringe (100) with a syringe barrel (101) and a syringe tip (102) and a package (1) suitable and intended for receiving the pre-fillable syringe (100), wherein the syringe tip (102) is provided with a tip cap (103), wherein the system (200) comprises a replacement cap (300) for the pre-fillable syringe (100), and wherein the package (1) is suitable and intended for receiving the replacement cap (300).
The package (1) suitable and intended for receiving a pre-fillable syringe (100)
comprises a syringe barrel (101) and a syringe tip (102), wherein the syringe tip (102) is provided with a tip cap (103), wherein the package (1) is suitable and intended for receiving a replacement cap (300) for the pre-fillable syringe (100).
The package (1) comprises a package body (3), forming a first cavity (4), defined by a sidewall (5) and a bottom wall (6), wherein the pre-fillable syringe (100) is arrangeable or arranged in said first cavity (4). The package body (3) extends along a longitudinal axis (X), a horizontal axis (Y), and a vertical axis (Z), which are perpendicular to each other. Further, the package body (3) has a rectangular shape.
At least one second receiving element (7, 7a, 7b) is provided in the first cavity (4) of the package body (3), in which the syringe barrel (101) is receivable. The embodiments shown in the figures have two second receiving elements (7, 7a, 7b), which are arranged at the bottom wall (6) of the package body (3).
The first (7a) of the second receiving elements (7) comprise a semicircular top section (26) arranged on a base section (27). The semicircular top section (26) is dimensioned to receive the syringe barrel (101). According the embodiments in Figs. 6 to 8, the second (7b) of the second receiving elements (7) also comprises a semicircular top section (26) arranged on a base section (27).
A distal end (101a) of the syringe barrel (101) is supported by a first (7a) of the second receiving elements (7), and a proximal end (101b) of the syringe barrel (101) is supported by a second (7b) of the second receiving elements (7).
In case the pre-fillable syringe (100) is arranged in the package (1), the first (7a) of the second receiving elements (7) is located close to or at the region (110), where the syringe barrel (101) merges into the syringe tip (102). Further, the second (7b) of the second receiving elements (7) is located close to the finger flange (105) of the pre-fillable syringe (100) arranged in the package body (3).
The first cavity (4) of the package body (3) is provided with a third receiving element (8), in which the rod (104) of the pre-fillable syringe (100) is receivable or received. The third receiving element (8) comprises two walls (8a, 8b) extending along the
vertical axis (Z), forming a cavity in which the rod (105) is receivable or received. Further, the third receiving element (8) has a bottom wall, formed semicircularly, and connecting the walls (8a, 8b). The third receiving element (8) ends at its proximal end in a fixture element (30), in which the finger support (109) of the rod (104) is received.
Between the second of the second receiving elements (7, 7b) and the third receiving element (8), a gap (29) is formed. Through this gap (29), the finger flange (105) of the pre-fillable syringe (100) may project, when the pre-fillable syringe (100) is placed inside the package body (3). Thus, the finger flange (105) is sandwiched between the second (7b) of the second receiving elements (7) and the third receiving element (8), such that the pre-fillable syringe (100) is fastened in the package body (3).
The third receiving element (8) stretches, after the gap (29), essentially along the length of the section of the rod (104) projecting from the syringe barrel (101).
When the pre-fillable syringe (100) is placed in the package body (3), it is supported by the first (7a) of the second receiving elements (7), preferably by the second (7b) of the second receiving elements (7), and preferably by the third receiving element (8), in particular by the fixture element (30). Thus, in a state where the pre-fillable syringe (100) is in the package body (3), a central axis (111) of the pre-fillable syringe (100) extends parallel to the bottom wall (6) of the package body (3). The central axis (111) extends in a height L2 above the bottom wall (6) of the package body (3). The height L2 allows an easy grasping of the pre-fillable syringe (100).
The replacement cap (300) is arranged in the package (1), such that an opening (309) of the replacement cap (300) is oriented along a vertical axis (Z) of the package body (3). An opening area (309a) of the replacement cap (300) is oriented parallel to the bottom wall (6) of the package body (3). Preferably the center axis (307) of the replacement cap (300) is parallel to the height extension of the sidewalls (5) of the package body (3).
The side wall(s) (5) of the package body (3) surround the package body (3) along the longitudinal axis (X) and the horizontal axis (Y). The sidewall(s) (5) extend(s) along the vertical axis (Z) with a height L4. The height L4 is at least the height L2 plus the radius
(112) of the syringe barrel (101). The upper (along the vertical axis (Z)) end of the side wall(s) (5) is provided with a flange (31). The flange (31) extends outwards and surrounds the package body (3) along the longitudinal axis (X) and the horizontal axis (Y), preferably without any gap.
On the flange (31), a closure element (15) may be arranged. Preferably the closure element is connected with a suitable connection to the flange (31). The closure element (15) is shown only partly in Fig. 6 and may be a foil or a slidable stable element.
According to the embodiment of Figs. 6 to 8, the first cavity (4) of the package body (3) is provided with a first receiving element (2), in which the replacement cap (300) is received. In particular, wherein the foot portion (303) of the replacement cap (300) is received in the first receiving element (2). The first receiving element (2) therefore essentially is the shape of the outer perimeter of the foot portion (303). In case of the Figs. 6 to 8 this shape would be essentially circular with a cut portion extending along a secant.
The first receiving element (2) comprises a sidewall (12), which is arranged on the bottom wall (6) of the package body (3). This sidewall (12) and the sidewall (5) of the package body (3) define a cavity, which complies with the shape of the foot portion (303) of the replacement cap (300). In the present case of Figs. 6 to 8, this cavity and the foot portion (303) of the replacement cap (300) are shaped essentially circularly. The bearing surface (311) of the replacement cap (300) sits therefore on the bottom wall (6) of the package body (3), such that the replacement cap (300) is arranged in the package (1), such that an opening (309) of the replacement cap (300) is oriented along a vertical axis (Z) of the package body (3). An opening area (309a) of the replacement cap (300) is oriented parallel to the bottom wall (6) of the package body (3).
The height (13) of the sidewall (12) along the vertical axis (Z) is essentially the height (310) of the replacement cap (300) at its outer edge.
In the Figs. 1 to 8, also a use of the system (200) is displayed. The use comprises preferably removing the closure element from the package body (3). The pre-fillable syringe (100) is then retrieved from the package (1). Then, the tip cap (103) is removed.
Optionally, the dosage of the pre-fillable syringe is set. Then, the replacement cap (300) is mounted on the pre-fillable syringe (100). For this, the syringe tip (102) is placed in the replacement cap (300) which is arranged in the package (1). The syringe tip (102) is let through the opening (309) of the replacement cap (300) and the opening (304) of the inner cap (301). Eventually, the inner cap (301) is attached to the syringe tip (102) and the ring (305) or the struts (306) abut on the syringe barrel (101). During the mounting, the replacement cap (300) is still inside the package (1). Since the opening (309) of the replacement cap (300) is oriented along the vertical axis (Z) of the package body (3), the syringe tip (102) may easily be introduced into the replacement cap (300). The handling of the syringe (100) is therefore possible using only one hand. It is not necessary to put the pre-fillable syringe (100) down to obtain or align the replacement cap (300) relative to the pre-fillable syringe (100). The pre-fillable syringe (100) with the replacement cap (300) attached to it may then be retrieved from the package (1).
The pre-fillable syringe (100) may preferably be placed in an upright position on a support surface (400). Preferably, a foot portion (303) of the replacement cap (300) is suitable to provide a stable upright positioning of the pre-fillable syringe (100) with the replacement cap (300) on the support surface (400), wherein a bearing area (311) of a foot portion (303) of the replacement cap (300) contacts the support surface (400).
Such a system (200) has the advantage that a package (1) is presented to the user which comprises the pre-fillable syringe (100) to use and a suitable replacement cap (300). The replacement cap (300) is already available to the user and does not need to be obtained otherwise. Further, the replacement cap (300) does not need to be retrieved from an additional package.
The invention is also directed to the system herein disclosed, wherein the syringe is pre-filled with a ready-to-use pharmaceutical formulation.
Advantageously, the pharmaceutical formulation is in form of solution or emulsion and comprises one or more active ingredients suitable for oral, intramuscular or intravenous administration.
More advantageously, the formulation is an aqueous solution or a hydroalcoholic solution.
Preferably, the pharmaceutical formulation is an aqueous solution or a hydroalcoholic solution comprising buprenorphine, for an efficacious treatment by sublingual and/or buccal administration of patients affected by opiate withdrawal syndrome (OWS), more preferably neonates affected by neonatal OWS.
More preferably, the buprenorphine formulation in form of aqueous solution comprises:
i) from 0.005 to 0.02% w/v of buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient;
ii) from 0.5% to 10% w/v of a thickening agent; and
iii) a buffering agent in an amount to provide a pH of 5.0-7.0.
Buprenorphine shall be utilized as a base or in the form of a pharmaceutically acceptable salt formed with an inorganic or organic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid.
Preferably, buprenorphine is present as the hydrochloride salt.
Advantageously, the concentration of buprenorphine, expressed as free base, shall be comprised between 0.005 and 0.02% w/v, preferably between 0.006 and 0.01% w/v, expressed as free base.
In a particular embodiment, the concentration of buprenorphine hydrochloride is 0.0075% w/v, expressed as free base.
The concentration of the thickening agent shall be comprised between 0.5% and 10%, w/v, preferably between 0.6%and 8.0% w/v. The type and amount of the thickening agent shall be properly selected to achieve an adequate viscosity to retain the formulation
as much as possible under the tongue of the patient, to minimize the absorption through the gastrointestinal tract.
At the same time, the viscosity should be not too high to retard the release of the active ingredient from the matrix and hence, its local absorption.
More preferably, the concentration of the thickening agent may be between 1.0 and 6.0% w/v.
In particular embodiments, said concentration is 1.0% w/v, or 1.5% w/v, or 2.0% w/v, or 6.0% w/v.
Advantageously, the thickening agent may be selected from water-soluble polysaccharides such as alginates, carrageenans, pectin, water-soluble derivatives of cellulose: alkylcelluloses hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose (HPMC); carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts; water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP) and polycrotonic acids; also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or quaternary amino group, such as the diethylaminoethyl group, which may be quatemized if desired.
Preferably, the thickening agent is a water-soluble cellulose derivative selected from group consisting of hydroxyethylcellulose (HEC) or an alkali metal salt of carboxymethylcellulose (CMC) such as the sodium salt.
In fact, the thickening agents belonging to said classes may provide the suitable
viscosity, while with other agents of the class of gums, such as xanthan gum, the viscosity of the formulation turned out to be too high.
Advantageously, the viscosity of the formulation at 25 ± 2°C shall be comprised between 500 and 2300 mPas (1 mPas corresponds to 1 centipoise), preferably between 700 and 2100 mPas The viscosity may be determined by any known method, for example using a rheometer.
Advantageously, the pH of the formulation of the invention may be comprised between 5.0 and 7.0, more advantageously between 5.2 and 6.8, preferably between 5.5 and 6.5.
When a water soluble cellulose derivative is used, preferred formulations have a pH between 5.5 and 6.5 and an amount of thickening agent comprised between 1.0% and 2.0% w/v, even more preferably of 1.5% w/v. The preferred thickening agent of this class may be hydroxy ethylcellulose. Said excipient is commercially available as Natrosol 250 HXTM.
Any buffering agent able of providing the pH maybe used, for example phosphate or citrate buffers as sodium or potassium salts. The skilled person in the art shall determine the proper amount.
In a preferred embodiment, anhydrous citric acid and sodium citrate anhydrous is used as buffering agent.
Said formulation may also contain other excipients such as flavoring agents and/or sweeteners.
Flavoring agents may be chosen from natural and synthetic flavoring liquids. An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof. A representative list of examples includes mint oils, cocoa, and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
Other useful flavorings include aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alpha-citral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof and the like.
The sweeteners may be chosen from the following non-limiting list: glucose (com syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and the like. Also contemplated are hydrogenated starch hydrolysates and the synthetic sweetener 3,6- dihydro-6-methyl-l-l-l, 2, 3-oxathiazin-4-one-2, 2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof. Other sweeteners may also be used.
Typically, the skilled person in art shall select the sweetener and/or flavoring agent among those considered safe for neonatal administration.
Said formulation may also contain permeation enhancers such as propylene glycol, and polyoxyl hydrogenated castor oil derivatives, for example polyoxyl 40 hydrogenated castor oil (commercially available as Kolliphor RH 40TM).
In preferred embodiment, the formulation has the following composition: 0.05-0.01% w/v buprenorphine hydrochloride expressed as a base, 1.5% w/v hydroxyethylcellulose, 0.12% w/v anhydrous citric acid, 1.13% w/v sodium citrate anhydrous, water for injection, and its pH is of 6.0 ± 0.3.
In an alternative embodiment, the formulation may have the following composition: 0.05-0.01% w/v buprenorphine hydrochloride expressed as a base, 6.0% w/v sodium carboxymethylcellulose, 0.12% w/v anhydrous citric acid, 1.13% w/v sodium citrate anhydrous, water for injection, and its pH is of 6.0 ± 0.3.
More details are reported in the International PCT patent application no. PCT/EP2018/078447 and US application no. 16/164,282, the entire content of each of
which is incorporated herein by reference.
The pharmaceutical formulations can be prepared according to known methods.
In a preferred embodiment, the pharmaceutical formulation is sterile and pre-filling is carried out under aseptic conditions is carried out according to methods known in the art.
Even though it less preferred, the pharmaceutical formulation can be in form of a dry powder to be dissolved extemporaneously before use.
Therefore, the invention is also directed to a kit comprising the system herein disclosed together with a pharmaceutical formulation in form of either ready-to-use aqueous solution or powder to be reconstituted in a suitable vehicle, and instructions to administer said pharmaceutical formulation.
Claims (1)
- 1. System (200) comprising a pre-fillable syringe (100) with a syringe barrel (101) and a syringe tip (102) and a package (1) suitable for receiving the pre-fillable syringe (100), wherein the syringe tip (102) is provided with a tip cap (103),characterized in thatthe system (200) comprises a replacement cap (300) for the pre-fillable syringe (100), wherein the package (1) is suitable for receiving the replacement cap (300).2. System (200) according to claim 1,characterized in thatthe package (1) comprises a package body (3) forming a first cavity (4), defined by a sidewall (5) and a bottom wall (6), wherein the pre-fillable syringe (100) is arranged in said first cavity (4), wherein at least one second receiving element (7, 7a, 7b) is provided in the first cavity (4) of the package body (4), in which the syringe barrel (100) is received, wherein a distal end (101a) of the syringe barrel (101) is supported by a first (7a) of the second receiving elements (7) and a proximal end (101b) of the syringe barrel (101) is supported by a second (7a) of the second receiving elements (7).3. System (200) according to any of claims 1 or 2,characterized in thatthe replacement cap (300) is arranged in the package (1), such that an opening (309) of the replacement cap (300) is oriented along a vertical axis (Z) of the package body (3), wherein an opening area (309a) of the replacement cap (300) is oriented parallel to the bottom wall (6) of the package body (3).4. System (200) according to any of claims 1-3,characterized in thatat least one third receiving element (8) is provided in the first cavity (4) of the package body (3), in which a rod (104) of the pre-fillable syringe (100) is received, wherein a gap (29) between the second (7b) of the second receiving elements (7) and the third receiving element (8) is provided, wherein a finger flange (105) of the pre-fillable syringe (100) projects through said gap (29) such that the finger flange is sandwiched between second (7b) of the second receiving elements (7) and the third receiving element (8).5. System (200) according to any of claims 1-4,characterized in thatthe replacement cap (300) comprises an inner cap (301) for an engagement with the syringe tip (102), an outer collar (302) engaging with the syringe barrel (101) for mounting the replacement cap (300) on the syringe barrel (101) and a foot portion (303).6. System (200) according to any of the claims 2 to 4,characterized in thata first receiving element (2) is provided in the first cavity (4) of the package body (4), wherein the replacement cap (300) is received in the first receiving element (2), wherein the foot portion (303) of the replacement cap (300) is received in the first receiving element (2).7. System (200) according to claim 4,characterized in thatthe foot portion (303) is suitable to provide a stable upright positioning of the pre-fillable syringe (100) with the replacement cap (300) on a support surface (400), wherein the foot portion (303) comprises a bearing area (311), which contacts the support surface (400), wherein the bearing area (311) comprises an edge (313), which surrounds a center axis(307) of the replacement cap (300) at an edge-distance (308), wherein the edge-distance(308) is at least twice the radius (112) of the syringe barrel (101), wherein the foot portion (303) has a disc-like shape.8. System (200) according to any of the preceding claims,characterized in thatthe sidewall (5) of the package body (3) is provided with a flange (31) on its upper end, wherein the package (1) comprises a closure element, which covers the package body (3) at least in part, wherein the closure element is arranged on the flange (31).9. Package (1) suitable and intended for receiving a pre-fillable syringe (100) comprising a syringe barrel (101) and a syringe tip (102), wherein the syringe tip (102) is provided with a tip cap (103),characterized in thatthe package (1) is suitable and intended for receiving a replacement cap (300) for the pre-fillable syringe (100).10. Package (1) according to claim 9,characterized in thatthe package (1) comprises a package body (3) forming a first cavity (4), defined by a sidewall (5) and a bottom wall (6), wherein the pre-fillable syringe (100) is arranged in said first cavity (4), wherein at least one second receiving element (7, 7a, 7b) is provided in the first cavity (4) of the package body (4), in which the syringe barrel (100) is received,11. Package (1) according to claim 10,characterized in thata first receiving element (2) is provided in the first cavity (4) of the package body (4), wherein the replacement cap (300) is received in the first receiving element (2), such that the replacement cap (300) is oriented along a vertical axis (Z) of the package body (3) and an opening area (309a) of the replacement cap (300) is oriented parallel to the bottom wall(6) of the package body (3), wherein the foot portion (303) of the replacement cap (300) is received in the first receiving element (2).12. Package (1) according to any of the claims 10 or 11,characterized in that at least one third receiving element (8) is provided in the first cavity (4) of the package body (3), in which a rod (104) of the pre-fillable syringe (100) is receivable, wherein a gap (29) between the second (7b) of the second receiving elements(7) and the third receiving element (8) is provided, wherein a finger flange (105) of the pre-fillable syringe (100) may project through said gap (29) such that the finger flange (105) is sandwiched between second (7b) of the second receiving elements (7) and the third receiving element (8).13. Replacement cap (300) for a pre-fillable syringe,characterized in thatthe replacement cap (300) comprises an inner cap (301) for an engagement with the syringe tip (102), an outer collar (302) engaging with the syringe barrel (101) for mounting the replacement cap (300) on the syringe barrel (101) and a foot portion (30), which is suitable to provide a stable upright positioning of the pre-fillable syringe (100) with the replacement cap (300) on a support surface (400).14. Replacement cap (300) according to claim 13,characterized in thatthe foot portion (303) comprises a bearing area (311), which contacts the support surface (400), wherein the bearing area (311) comprises an edge (313), which surrounds a center axis (307) of the replacement cap (300) at an edge-distance (308), wherein the edge-distance (308) is at least twice the radius (112) of the syringe barrel (101), wherein the foot portion (303) has a disc-like shape.15. Use of a system (200) according to any of the claims 1 to 8, comprising the following steps:a) retrieving the pre-fillable syringe (100) from the package (1);b) removing the tip cap (103) from the syringe tip (102);c) placing the syringe tip (102) in the replacement cap (300), which is arranged in the package (1); andd) retrieving the pre-fillable syringe (100) with the replacement cap (300) attached to it from the package (1).16. System (200) according to any of the preceding claims 1 to 8, wherein the syringe is pre-filled with a ready-to-use pharmaceutical formulation.17. System (200) according to claim 16, wherein the pharmaceutical formulation is in form of solution or emulsion and comprises one or more active ingredients suitable for oral, intramuscular or intravenous administration.18. System (200) according to claim 16 or 17, wherein the formulation is an aqueous solution or a hydroalcoholic solution.19. System (200) according to any one of claims 16 to 18, wherein the pharmaceutical formulation is an aqueous solution or a hydroalcoholic solution for sublingual and/or buccal administration comprising buprenorphine as active ingredient.20. A kit comprising the system according to any one of claims 1 to 8 and 16-19, together with a pharmaceutical formulation in form of either ready-to-use aqueous solution or powder to be reconstituted in a suitable vehicle, and instructions to administer said pharmaceutical formulation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19163093 | 2019-03-15 | ||
EP19163093.8 | 2019-03-15 | ||
PCT/EP2020/056480 WO2020187660A1 (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020244071A1 true AU2020244071A1 (en) | 2021-09-02 |
Family
ID=65817887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020244071A Pending AU2020244071A1 (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3938010A1 (en) |
JP (1) | JP2022523408A (en) |
KR (1) | KR20210141501A (en) |
CN (1) | CN113573752A (en) |
AU (1) | AU2020244071A1 (en) |
BR (1) | BR112021015970A2 (en) |
CA (1) | CA3130030A1 (en) |
MA (1) | MA55294A (en) |
MX (1) | MX2021010362A (en) |
WO (1) | WO2020187660A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444310A (en) * | 1982-07-26 | 1984-04-24 | Becton, Dickinson And Company | Segmented multi-product package assembly |
AUPN540595A0 (en) * | 1995-09-13 | 1995-10-05 | Needle Technology (Aust) Limited | Needle housing |
WO2014045336A1 (en) * | 2012-09-18 | 2014-03-27 | テルモ株式会社 | Syringe packaging container |
WO2015107774A1 (en) * | 2014-01-16 | 2015-07-23 | テルモ株式会社 | Syringe for injecting drug solution into upper skin layer |
TWI737742B (en) * | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | Botulinum toxin prefilled syringe system, kit having the same and use thereof |
JP6933651B2 (en) * | 2016-08-23 | 2021-09-08 | テルモ株式会社 | Medical device packaging |
-
2020
- 2020-03-11 MA MA055294A patent/MA55294A/en unknown
- 2020-03-11 KR KR1020217029582A patent/KR20210141501A/en unknown
- 2020-03-11 AU AU2020244071A patent/AU2020244071A1/en active Pending
- 2020-03-11 WO PCT/EP2020/056480 patent/WO2020187660A1/en active Application Filing
- 2020-03-11 JP JP2021552171A patent/JP2022523408A/en active Pending
- 2020-03-11 CN CN202080020984.3A patent/CN113573752A/en active Pending
- 2020-03-11 EP EP20714881.8A patent/EP3938010A1/en active Pending
- 2020-03-11 MX MX2021010362A patent/MX2021010362A/en unknown
- 2020-03-11 BR BR112021015970-3A patent/BR112021015970A2/en unknown
- 2020-03-11 CA CA3130030A patent/CA3130030A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3130030A1 (en) | 2020-09-24 |
EP3938010A1 (en) | 2022-01-19 |
JP2022523408A (en) | 2022-04-22 |
WO2020187660A1 (en) | 2020-09-24 |
MX2021010362A (en) | 2021-09-30 |
KR20210141501A (en) | 2021-11-23 |
BR112021015970A2 (en) | 2021-10-05 |
CN113573752A (en) | 2021-10-29 |
MA55294A (en) | 2022-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11369733B2 (en) | System comprising a pre-fillable syringe and a package for the pre-fillable syringe | |
GB2108841A (en) | Sustained release layered pharmaceutical compositions | |
BR112019027508A2 (en) | nasal dosage forms of dihydroergotamine | |
TW201143758A (en) | Syringe filter cap and method of using the same for administration of medication dosage | |
CN113613645B (en) | Transmucosal therapeutic system containing agomelatine | |
US11351299B2 (en) | System comprising a pre-fillable syringe and a package for the pre-fillable syringe | |
JP4588281B2 (en) | Oxcarbazepine-containing suspension | |
Niu et al. | FDA perspective on peptide formulation and stability issues | |
WO1999051237A1 (en) | Oral liquid antidepressant solution | |
WO2020187660A1 (en) | System comprising a pre-fillable syringe and a package for the pre-fillable syringe | |
CA3202161A1 (en) | Liquid apixaban formulation in small dose volume | |
RU2811660C2 (en) | System containing pre-filled syringe and packaging for pre-filled syringe | |
US20200237650A1 (en) | Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof | |
US20160030723A1 (en) | Multi-Chamber Anesthetic Delivery System | |
KR102660711B1 (en) | Pharmaceutical preparations comprising an opioid receptor agonist as an active ingredient, methods for their preparation and therapeutic use | |
RU2795099C2 (en) | Pharmaceutical compositions containing an opioid receptor agonist as active ingredient, methods of their production and their therapeutic use | |
CN113597303A (en) | Transmucosal therapeutic system containing agomelatine | |
AU2004203644B2 (en) | Pharmaceutical compositions |